June 23, 2015

Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM Capital

Cambridge/June 22, 2015 – MPM Capital announces the appointment of Briggs W. Morrison, M.D., to the position of Managing Director (MD). Dr. Morrison was recently appointed Chief Executive Officer of Syndax Pharmaceuticals, Inc., an MPM portfolio company, after serving as Chief Medical Officer and Executive Vice President for R&D at AstraZeneca.

“Briggs’ career as a leader in developing drugs across a range of complex diseases underscores his deep commitment to advancing treatments for patients with debilitating unmet needs,” said Luke Evnin, MPM Capital Managing Director and co-founder. “Briggs constructed a compelling product pipeline at AstraZeneca, which includes five NCEs as well as line extensions for existing cancer therapeutics. We are tremendously excited about the prospects for Syndax under his leadership and look forward to Briggs sharing his expertise across MPM’s portfolio as we advance into new arenas with our recently closed BV2014 fund.”

In his role as head of global medicines development, Dr. Morrison oversaw all clinical development functions and late stage clinical development projects at AstraZeneca. During his tenure, AstraZeneca rebuilt its Phase 3 pipeline with a focus on Oncology, Respiratory, and Cardiovascular/Metabolic molecules. Prior to joining AstraZeneca Dr. Morrison served as Head of Clinical Development at Pfizer, overseeing Phase I – III development for all therapeutic areas as well as clinical operations. When Pfizer established its Business Unit model in 2009, Dr. Morrison became head of the Medicines Development Group for the Primary Care Business Unit, overseeing Development, Medical Affairs, Market Access, and early commercial development for Pfizer’s largest Business Unit. He later oversaw Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses.

Earlier in his career Dr. Morrison ran the Clinical Data Management organization at Merck, in which he was accountable for global data management operations for all Merck clinical trials. At Merck he worked directly with the President of Merck Research Labs to lead the restructuring of the research division and its processes – further improving execution of Merck’s clinical development programs. He then was named head of the Oncology Development group at Merck, overseeing the development and approval of vorinostat (Zolinza) for the treatment of cutaneous T-cell lymphoma.

Dr. Morrison serves as Chairman of the Board of Transcelerate, an industry-funded company charged with improving aspects of clinical trials. He is also a member of the Executive Committee of CTTI (the Clinical Trials Transformation Initiative sponsored by FDA) and is on the Board of ACRES (Alliance for Clinical Research Excellence and Safety).

Dr. Morrison received his BS (Biology) degree from Georgetown University and his MD degree from the University of Connecticut. He completed his internship and residency in Internal Medicine at the Massachusetts General Hospital, his fellowship in Medical Oncology at the Dana-Farber Cancer Institute, and completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School under the guidance of Dr. Philip Leder. He completed additional post-doctoral work under the guidance of Dr. Lee Nadler at the Dana-Farber Cancer Institute.

About MPM Capital — MPM Capital (http://www.mpmcapital.com) is a global leader in early-stage life sciences venture investing with a track record of success in building world-class companies around transformational treatments and cures. With its deep experience, dedicated team of operating executives and distinguished MSAB, MPM Capital is powering medical breakthroughs that change lives.

###

FOR FURTHER INFORMATION:

Sarah Reed +1.617.425.9205
sreed@mpmcapital.com